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Introduction: Gaining a higher response rate (RR) has usually been
determined as a primary end point in phase II trials evaluating the
efficacy of new molecular targeted drugs. However, a relationship
between clinical response and survival benefit has not been well
studied in the patients treated with molecular targeted agents.
Methods: Prospective trials of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) monotherapy in non-small
cell lung cancer were extracted from MEDLINE, EMBASE, and the
annual meetings in 2007 of the American Society of Clinical
Oncology, European Cancer Conference, and World Conference on
Lung Cancer.
Correlation between clinical response and survival was ex-
amined using linear regression analysis. We also tried to compare
the significance of RR as surrogate markers for survival with that of
disease control rate (DCR) by calculating the area under their
receiver operating characteristic (ROC) curves.
Results:We identified 24 phase II trials and 4 phase III trials with
a total of 6171 patients and 30 treatment arms, including 22 arms
for the gefitinib group and 8 arms for the erlotinib group. Both
RR and DCR strongly correlated with median survival time
(MST; p  0.0001 and p  0.003, respectively). In an ROC
analysis, the area under the ROC curve predicting MST prolon-
gation by RR was 0.918, which was higher than the area under
the ROC curve by DCR.
Conclusions: We found a significant relationship between RR and
MST in clinical trials with EGFR-TKIs. RR could be an independent
surrogate marker for MST in the current response criteria in the
clinical trials of EGFR-TKIs.
Key Words: Non-small cell lung cancer, Gefitinib, Erlotinib,
EGFR, Response rate.
(J Thorac Oncol. 2009;4: 994–1001)
The small-molecule inhibitors of epidermal growth factorreceptor (EGFR), gefitinib (Iressa, AstraZeneca Pharma-
ceuticals, Wilmington, DE), and erlotinib (Tarceva, Genen-
tech, South San Francisco, CA) have shown antitumor activ-
ity in patients with non-small cell lung cancer (NSCLC).
These drugs are orally bioavailable synthetic anilinoquinazo-
lines that selectively and reversibly prevent ATP binding and
autophosphorylation of the EGFR tyrosine kinase.
Gaining a higher response rate (RR) has usually been
determined as a primary end point in phase II trials
evaluating the efficacy of new molecular targeted drugs1,2
and often in the correlative studies that have been conducted
to find out the molecular and clinical predictors of survival in
the treatment of EGFR tyrosine kinase inhibitors (EGFR-
TKIs). However, a relationship between clinical response and
survival benefit has not been well studied to date in the
patients treated with molecular targeted agents, such as
EGFR-TKIs, although survival benefit is usually the most
reliable index to be tested.
Furthermore, the same objective tumor response crite-
ria as cytotoxic agents, which are mainly known as World
Health Organization (WHO) and Response Evaluation Crite-
ria in Solid Tumors Group (RECIST) criteria, have been used
in phase II trials of molecular targeted agents, although they
seemed to be different from cytotoxic agents in their tumor
killing mechanism. It has not been well investigated whether
these criteria are appropriate for evaluating the potential
antitumor effect of molecular targeted agents. Disease stabi-
lization, not tumor shrinkage, may be the main impact of
molecular targeted agents on tumor growth, because many of
these agents may affect tumor cells by reducing proliferation
rather than by causing cell death. In the analysis of a ran-
domized, placebo-controlled, double-blind trial conducted by
Shepherd et al.,3 the patients treated with erlotinib have been
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shown to have a survival advantage compared with those
given a placebo even if we censor the patients who have
responded. These results may suggest that RR is not an
adequate end point for phase II studies of EGFR-TKIs.
The purpose of this study was to clarify through a
systematic review of publications the significance of RR,
stable disease rate (SDR), and disease control rate (DCR) in
the current criteria as a surrogate end point for survival in the
treatment of advanced NSCLC with EGFR-TKIs, gefitinib,
and erlotinib. It will be worthwhile to examine such a rela-
tionship, because molecular targeted agents are expected to
play a more important role than ever for cancer treatments,
and the clinical predictors of outcome in NSCLC patients will
be required in clinical trials using molecular targeted agents.
MATERIALS AND METHODS
Literature Search and Data Extraction
Prospective trials of EGFR-TKIs monotherapy in
NSCLC, published by December 31, 2007, were identified
from MEDLINE, EMBASE, using the keywords “nonsmall
cell lung cancer” and “gefitinib,” “ZD1839,” “Iressa,” “erlo-
tinib,” or “tarceva.” A manual search was performed for
abstracts presented at the annual meetings of the American
Society of Clinical Oncology, European Cancer Conference,
and World Conference on Lung Cancer in 2007. All results
were limited to phase II trial or phase III trial and those
written in the English language. In consideration of the
accuracy of data, reports of trials with a sample size of at least
30 patients per arms were included if they contained mature
data on RR and median survival time (MST). Trials using the
agents in combination were excluded.
For each trial, data on sample size, kind of EGFR-TKIs,
RR, SDR, DCR, MST, and median time to progression
(MTTP) or median progression-free survival (MPFS) were
collected. Such patient characteristics of each study as gen-
der, performance status (PS), clinical stage, number of prior
chemotherapy, ethnicity, response criteria, and age were also
extracted. MST, MTTP, or MPFS on each study was deter-
mined using published data or survival curves.
Statistical Analysis
Correlation between clinical response (RR and DCR)
and survival (MST and MPFS) was examined in each study
using linear regression analysis. We also tried to compare the
significance of RR as surrogate markers for survival with that
of DCR by calculating the area under their receiver operating
characteristic (ROC) curves. In this model, ROC curves
examined the accuracy of each surrogate marker to predict
whether MST of each study arm was longer than 7.6 months
or not, which was the median MST among every study arm.
An index of 0.5 indicates no discrimination ability, whereas
a value of 1 indicates perfect discrimination.
In linear regression analysis, we analyzed not only
MST but also MPFS, because MPFS has often been used as
a primary end point, which is not affected by effective
subsequent therapies, instead of MST in the studies of clinical
oncology. If data about MPFS were not mentioned and only
MTTP or median time to treatment failure (MTTF) was
available in published data or survival curves, they were
calculated the same as MPFS when examining correlation
between clinical response and MPFS. As some differences
were seen in their definition4,5 (Table 1), we checked whether
there was not a major difference among them when correlated
with RR by calculating the linear regression line in the figure.
There could be some correlations among RR, SDR, and
DCR, and they might influence the result of our analyses.
Accordingly, we examined a relation between them by linear
regression analysis.
Moreover, this analysis was performed on many heter-
ogeneous studies with different kinds of patient characteris-
tics, and these differences might possibly lead to false con-
clusions. Therefore, we investigated the influence of such
patient characteristics on MST, MPFS, and RR as gender, PS,
histologic subtypes of cancer, number of prior chemothera-
pies, ethnicity, and types of EGFR-TKIs using Student t test.
A p value 0.05 was considered statistically signifi-
cant, and all reported p values were two sided. All statistical
analyses were performed using SPSS 16.0 for Windows
(SPSS, Inc., Chicago, IL).
RESULTS
Study Characteristics
We identified 28 trials of EGFR-TKIs monotherapy
with a total of 6171 patients and 30 treatment arms,
including 22 arms for the gefitinib group and 8 arms for the
erlotinib group. There were 24 phase II trials and 4 phase
III trials. The baseline characteristics of the 28 trials with
30 treatment arms are shown in Table 2.3,6–32 Nine studies
were identified from the abstracts presented at the confer-
ence meetings. Among them, four studies29–32 have been
published already, and all the data of these studies were
collected from final publications.
TABLE 1. Definition of Each Endpoint4,5
Abbreviation TTP PFS TTF
Written in full Time to progression Progression-free survival Time to treatment failure
Definitiona The time elapsed between treatment
initiation and tumor progression
The time elapsed between treatment
initiation and tumor progression
or death from any cause
The time elapsed between treatment initiation and
treatment discontinuation for any reason, including
disease progression, treatment toxicity, patient
preference, or death
a PFS differs from TTP in that PFS includes death as a result of any cause in its definition in addition to tumor progression. TTF uses treatment discontinuation as a result of
any cause instead of tumor progression in its definition.
PFS, progression-free survival; TTP, time to progression; TTF, time to treatment failure.
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The sample size of each arm ranged from 30 to 1129
patients, with a median sample size of 86 patients. Nine
treatment arms reported MTTP, 17 reported MPFS, 1 re-
ported MTTF, and 3 did not report either. RR and MST were
reported in all the treatment arms, whereas SDR was not
reported in two treatment arms. Nine arms were intended
only for chemotherapy-naive patients, 14 arms were only for
chemotherapy-received patients, and 7 arms contained both
of them. The cancer histology type was restricted to adeno-
carcinoma in four arms, whereas no arms restricted patients’
eligibility in those found to have EGFR mutations in their
tumors. Eleven arms had been conducted in Asian countries,
including four arms in Japan, two in China, two in Korea, two
in Taiwan, and one in Singapore. Evaluation for response was
conducted according to RECIST criteria in 21 treatment arms
and WHO criteria in 9 arms. RR and MST in the treatment
arms ranged from 3.1 to 55.6% (median: 15.2%) and from 3.9
to 19.7 months (median: 7.6 months), respectively.
Correlations among Clinical Response
RR and SDR were shown to have negative relationships
with each other by linear regression analysis, whereas RR and
DCR had positive relationships (Figure 1). Thus, it seemed
that there were some limitations in evaluating the true mean-
ing of correlation between SDR and MST, because they could
have been influenced strongly by these negative relationships.
We, therefore, analyzed DCR, rather than SDR, when inves-
tigating the correlation between disease stabilization and
survival in further analyses.
Median Survival Time
RR had a strong correlation with MST in the simple
linear regression analysis (Figure 2A, p  0.0001). Simi-
larly, DCR had a positive correlation with MST (Figure
2B, p  0.003). In terms of relationship between RR and
MST, there seemed to be no differences between gefitinib
arms and erlotinib arms, and between arms using WHO
TABLE 2. Characteristics of the Trials Included in the Analysis
Trial Phase
Treatment
Regimens No. of Patients RR (%) SDR (%) TTP (mo) PFS (mo) MST (mo)
Response
Criteria
Cappuzzo et al.6 II G 250 mg 63 15.9 42.8 3.3 — 4.1 R
Fukuoka et al.7a II G 250 mg 103 17.5 35.9 — 2.7 7.6 W
G 500 mg 109 19.1 32.4 — 2.8 8 W
Kris et al.8a II G 250 mg 106 11.8 30.4 — — 7 W
G 500 mg 115 8.8 27.2 — — 6 W
Cappuzzo et al.9 II G 250 mg 40 5 45 3 — 5 R
Cappuzzo et al.10 II G 250 mg 106 14.4 26.8 3.4 — 9.4 R
Ceresoli et al.11 II G 250 mg 41 9.8 17.1 — 3 5 R
Perez-Soler et al.12 II E 150 mg 57 12.3 35.1 — 2.1 8.4 W
Chen et al.13 II G 250 mg 36 33.3 38.9 4.7 — 9.5 W
Chiu et al.14 II G 250 mg 76 33.3 35.1 — 5 9.9 R
Han et al.15 II G 250 mg 90 23.3 30 2.7 — 7.4 W
Shepherd et al.3a III E 150 mg 488 8.9 36.1 — 2.2 6.7 R
Spigel et al.16 II G 250 mg 72 5.7 60.4 — 3.7 6.3 W
Thatcher et al.17a III G 250 mg 1129 8 32 — 3b 5.6 R
Giaccone et al.18 II E 150 mg 54 22.7 30.2 2.8 — 13 R
Lee et al.19 II G 250 mg 72 55.6 11.1 — 5.5 19.7 W
Lin et al.20 II G 250 mg 53 32.1 20.7 — 3.2 9.4 R
Niho et al.21 II G 250 mg 42 30 40 — — 13.9 R
Jackman et al.22 II E 150 mg 82 10 41 3.5 — 10.9 R
Wu et al.23 II G 250 mg 40 32 45 — 9 15 R
Goss et al.24a II G 250 mg 100 6 — — 1.2 3.9 R
Nishimura et al.25 II G 250 mg 30 23 27 — 3.2 11.9 R
Paz-Ares et al.26 II E 150 mg 879 18.8 39 3.9 — 6.1 R
Tamura et al.27 II E 150 mg 108 28.3 20.8 2.5 — 13.8 R
Tan et al.28 II E 150 mg 264 14 30 — 2.6 7.6 R
Crinò et al.29a II G 250 mg 97 3.1 40.2 — 2.6 5.9 R
Kim et al.30a III G 250 mg 733 9.1 — — 2.2 7.6 R
Maruyama et al.31a III G 250 mg 245 22.5 34 — 2 11.5 R
Hesketh et al.32 II E 150 mg 81 8 34 — 2.1 5 R
a Randomized controlled trial.
b Time to treatment failure.
G, gefitinib; E, erlotinib; RR, response rate; SDR, stable disease rate; TTP, time to progression; PFS, progression free survival; MST, median survival
time; R, RECIST criteria; W, WHO criteria.
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criteria and RECIST criteria (Figure 2A). The coefficient 0.258
for RR indicated that MST increased 0.258 month with each 1%
increase in RR. Similarly, each 1% increase of DCR was
associated with an increase of 0.170 month in MST.
The influence of study characteristics on MST and RR
are summarized in Table 3. Study arms with a larger propor-
tion of females had a significantly longer MST than those
with a lower proportion of females (p  0.021). Study
groups, which had a larger proportion of patients with ade-
nocarcinoma histology, showed significantly longer MST
compared with a lower proportion of patients with adenocar-
cinoma histology (p  0.005). Study groups with a larger
proportion of never smokers showed significantly longer
MST than those with a lower proportion of never smokers
(p  0.004). Study arms conducted in Asian countries had a
statistically longer MST than those conducted in non-Asian
countries (p  0.001), indicating Asian ethnicity was corre-
lated with survival prolongation in the treatment of EGFR-
TKIs. Moreover, all these four study groups, which showed
longer MST, also had a higher RR compared with those with
shorter MST (p  0.026, 0.001, 0.001, and 0.001, re-
spectively), which were similar to previous published data on
the treatment of EGFR-TKIs. In contrast, study arms with a
larger proportion of patients with PS 2 to 4 showed a signifi-
cantly shorter MST than those with a lower proportion of poor
PS (p 0.047). No significant differences on MST were shown
between gefitinib arms and erlotinib arms, arms using WHO
criteria and those using RECIST criteria, and arms intended only
for chemotherapy-naive patients and those intended only for
chemotherapy-received patients.
FIGURE 1. A, Correlation between stable disease
rate and response rate. B, Correlation between
disease control rate and response rate. Each scat-
terplot is shown separately by study size and the
type of epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs). The linear regression
lines are shown.
FIGURE 2. A, Correlation between median sur-
vival time and response rate. B, Correlation be-
tween median survival time and disease control
rate. Each scatterplot is shown separately by study
size and the type of epidermal growth factor re-
ceptor tyrosine kinase inhibitors (EGFR-TKIs). The
linear regression lines are shown.
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The relationships between RR and MST were conspic-
uous when study arms were divided into two categories by
MST: study arms of which MST was more than 7.6 months
or not (Figure 3). In an ROC analysis, the area under the ROC
curve predicting MST prolongation by RR was 0.918, which
was higher than the area under the ROC curve by DCR, even
though both of them performed significantly better than
random guessing of MST prolongation (Figure 3, p  0.001
and 0.033, respectively).
Progression-Free Survival
Both RR and DCR significantly correlated with MPFS
(p 0.001 and0.001, respectively). There seemed to be no
major difference among MPFS, MTTP, and MTTF when
correlated with RR (Figure 4). Among each study character-
istics, only a proportion of females was significantly corre-
lated with MPFS prolongation, whereas a proportion of
patients with adenocarcinoma histology, proportion of never
smokers, or Asian countries’ studies tended to have relation-
ships with MPFS without statistical significance (Table 3).
The coefficient for RR was 0.072, indicating that a 1%
increase in the RR prolonged MPFS by 0.072 month. Simi-
larly, each 1% increase in DCR was associated with an
increase of 0.093 month in MPFS.
DISCUSSION
The most commonly used end point for phase III trials
and for the regulatory approval of new anticancer drugs is
overall survival (OS). The OS is clinically meaningful and
FIGURE 3. Receiver operating characteristic (ROC) curves ex-
amining whether median survival time (MST) was more than
7.6 months or not by RR (solid line) and disease control rate
(DCR; dotted line). A diagonal line stands for expected ROC
curve for random guessing of MST prolongation. The area un-
der the ROC curves for RR and DCR were 0.918 and 0.737,
respectively. RR, response rate; SDR, stable disease rate.
TABLE 3. The Influence of Study Characteristics on RR, MST, and PFS or TTP3,6–32
Characteristics of Studies Number
MST (mo) PFS/TTP (mo) RR (%)
Mean  SD p Mean  SD p Mean  SD p
Proportion of female (%)a
40 15 7.19  2.72 0.021 2.69  0.65 0.026 13.36  7.09 0.026
40 15 10.22  3.97 3.95  1.93 22.73  13.77
Type of EGFR-TKIs
Gefitinib 22 8.62  3.90 0.838 3.48  1.68 0.217 19.06  13.00 0.443
Erlotinib 8 8.94  3.27 2.70  0.68 15.35  7.41
Proportion of patients with PS 2–4 (%)a,b
20 14 9.99  4.14 0.047 2.98  0.94 0.411 19.60  12.63 0.465
20 15 7.28  2.76 3.49  1.89 16.27  11.45
Proportion of patients with adenocarcinoma (%)a
65 16 7.03  2.47 0.005 2.80  0.72 0.077 11.14  5.61 0.001
65 14 10.62  3.98 3.82  1.98 25.93  12.12
Patients type included in studiesc
Only chemotherapy-naïve patients 14 8.27  3.20 0.665 3.30  1.94 0.489 16.61  9.29 0.803
Only chemotherapy-received patients 9 8.91  3.72 2.78  0.83 15.51  11.38
Proportion of never smokers (%)a,d
25 12 7.38  2.87 0.004 2.64  0.76 0.062 10.04  7.02 0.001
25 11 11.70  3.60 3.93  2.03 29.10  10.67
Country where a study was conductede
Non-Asian country 14 6.91  2.65 0.001 2.85  080 0.085 11.29  5.15 0.001
Asian country 11 11.78  3.64 4.04  2.11 29.76  10.46
a Studies were divided into two groups with the median by each characteristics, and then they were compared with each other.
b One study25 was excluded because it did not have detail information about performance status.
c Seven studies10,11,14,15,19,26,28 were excluded because they contained both chemotherapy-naïve patients and chemotherapy-received patients.
d Five studies6–8,11,26 including seven arms were excluded because they did not have detail information about smoking status.
e Four studies7,17,29,30 including five arms were excluded because they were undertaken in many countries across Asia and non-Asia.
MST, median survival time; TTP, time to progression; PFS, progression free survival; SD, standard division.
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objectively measured but can be influenced by effective
sequential therapies. Furthermore, these phase III studies are
laborious, time consuming, and costly.33 A validated shorter
term surrogate end point would reduce drug development
costs and allow for more rapid completion of randomized
controlled trials. From such a point of view, some investiga-
tors34,35 have already examined the relationships between
surrogate end points including clinical response and survival
in the treatment of neoplasm with cytotoxic agents. However,
EGFR-TKIs, kinds of molecular targeted agents, seemed to
be different with cytotoxic agents in tumor killing mecha-
nism, and it was unclear how large an impact on survival the
clinical response with EGFR-TKIs had. To our knowledge,
this was the first analysis investigating the relationships
between clinical response and survival benefit in cancer
treatments with molecular targeted agents.
In this analysis, the MST prolongation for a 1% in-
crease in RR is higher than for a 1% increase in DCR,
although both RR and DCR were significantly related to MST
and MPFS. Additionally, the area under the ROC curve for
assessment of survival indicated that RR was a more accurate
marker than DCR when predicting MST prolongation. These
results suggest that it is more important to increase RRs than
to achieve stable disease to improve OS in the treatment of
EGFR-TKIs, although there may be some importance in
achieving stable disease.
It has not been well understood whether clinical re-
sponse obtained by EGFR-TKIs has similar impacts on sur-
vival benefit to that obtained by cytotoxic agents. Previously,
we reported36 an analysis examining the correlation between
clinical response and survival in the second-line treatment of
NSCLC using studies about cytotoxic agents and a small
number of studies about EGFR-TKIs. Although the results
indicated that there were some relationships between clinical
response and survival, there were very few studies of EGFR-
TKIs monotherapy in those days, and therefore we could not
detect the differences of these relationships between cyto-
toxic agents and EGFR-TKIs. The 0.0744-month increase of
MST by each 1% increase of RR in our previous report was
similar to published data of other cytotoxic agents studies in
NSCLC.34,37 However, the 0.258-month increase of MST by
each 1% increase of RR for EGFR-TKIs in this study was
about three times longer than that in previous studies of
cytotoxic agents. These findings suggest that the clinical
response of EGFR-TKIs could have a more close relationship
with survival prolongation than that of cytotoxic agents,
although further investigation will be necessary.
There are some limitations to our analysis. First, we
relied on summary data from many published trials to assess
the validity of surrogate end points. Trial-level surrogacy as
described here is not necessarily linked to individual-level
surrogacy,38 and so our data cannot be used to predict an
individual’s chance of survival on the basis of their response
to treatment. For instance, we may sometimes feel in clinical
practice that some patients continue to benefit from gefitinib
or erlotinib even after episodes of localized relapse. Our
analyses could not include such specific cases, although it
may be an important issue whether there is “clinical benefit
beyond progression” in some patients treated with gefitinib or
erlotinib.39 Further studies that are based on individual patient
data will be required to assess the real meaning of respon-
siveness to EGFR-TKIs on an NSCLC patient in clinical
practice. Furthermore, the value of response on survival
calculated in this study is based on EGFR-TKIs trials, and we
do not know whether the same relations will hold for other
molecular targeting agents, such as antibodies.
Second, there was potential bias in this study. Our
analysis contained many heterogeneous phase II studies with
different patient characteristics, and the method of evaluating
end points such as response, stable disease, and progression-
free survival (PFS) may not be exactly the same in each
study. Indeed, patients came from extended access programs
in some studies.9–16 Therefore, the quality of the results is
different from other closely monitored studies in terms of
PFS and RR. These differences might possibly lead to false
conclusions. In addition, we have no detailed information on
whether the evaluation of response and stable disease was
performed by physicians or others. In particular, the evalua-
tion method of the response is important as time to progres-
sion and PFS are the end points, which are influenced by the
value of the response. Moreover, several studies9–11 came
from the same center with overlapping selecting criteria. It
was not known whether there was some overlapping of the
analyzed patients.
In addition, patients registered in phase II studies are
generally required to have measurable lesions, whereas this is not
always required in phase III studies. This shows that the higher RRs
and selection bias tend to increase in phase II studies.
FIGURE 4. A, Correlation between progression-
free survival or time to progression and response
rate. B, Correlation between progression-free sur-
vival, time to progression, or time to treatment
failure and disease control rate. The linear regres-
sion lines are shown. PFS, progression-free sur-
vival; TTP, time to progression; TTF, time to treat-
ment failure.
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In terms of patient characteristics, our investigation
suggests that female gender, adenocarcinoma histology,
smoking status, ethnicity, and PS might have an influence on
MST. However, all of these characteristics except PS have
already been reported to be associated with RR, which was
confirmed in our analysis as well. Thus, we postulate that
these patient groups gained higher RRs by the treatment of
EGFR-TKIs, leading to higher MST in this study.
Third, our analysis did not contain an untreated control
arm for comparison. Therefore, strictly speaking, the results
of the analyses are unable to determine whether these findings
were caused by a differential effect of treatment on the
cancers in responded patients or by the indolent behavior of
cancers in responded patients. It is well known that the
presence of the EGFR mutation predicts a high RR after
treatment with gefitinib or erlotinib.40 In addition, some
investigators41,42 suggested that the presence of the EGFR
mutation was associated with longer survival, irrespective of
treatment. Therefore, the high RR of groups of patients after
receiving gefitinib or erlotinib may serve only as a surrogate
marker of their good prognosis after whatever systemic treat-
ments they received. Appropriate control, such as chemother-
apy or placebo, should be selected to evaluate the efficacy of
novel EGFR-TKI in drug evaluation studies.
Despite these limitations, a strong relationship was seen
between RR and MST in this study. These findings suggest
that RR could be a primary end point as a surrogate marker
of survival in the phase II trials and in the correlative studies
conducted to find out the molecular and clinical predictors of
survival in NSCLC treated with EGFR-TKIs. Furthermore,
they may allow researchers and oncologists to use clinical
response as a surrogate marker of survival in clinical trials of
NSCLC with a more objective estimate of how long an
EGFR-TKIs therapy with a known RR may, on average,
prolong life. Further analyses will be needed to assess
whether these findings could be applied to other types of
cancer or other kinds of molecular targeted agents.
In summary, using a systematic review of publications,
we found a significant relationship between RR and MST in
clinical trials with EGFR-TKIs using a linear regression
model. RR could be an independent surrogate marker for
MST in the current response criteria in clinical trials of
EGFR-TKIs. These findings may be supportive as further
trials for lung cancer and EGFR-TKIs are developed in the
future.
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